Skip to main content
. 2020 Jan 29;12(e2):e264–e270. doi: 10.1136/bmjspcare-2019-002037

Table 3.

Adverse events of grade ≥2 that occurred in >3% in either studied populations

Adverse events NEPA (n=60) Historical controls (APR) (n=62)
Grade Grade
0 1 2 3 4 0 1 2 3 4
Alanine transaminase 60 0 0 0 0 60 0 2 0 0
Constipation 32 28 0 0 0 52 8 2 0 0
Cough 56 1 3 0 0 53 9 0 0 0
Dyspepsia 55 2 3 0 0 60 1 1 0 0
Febrile neutropaenia 60 0 0 0 0 57 0 0 5 0
Infections 58 0 2 0 0 62 0 0 0 0
Mucositis—oral cavity 21 37 2 0 0 43 15 3 1 0
Neutropaenia 37 2 12 2 7 27 0 14 8 13
Pain 57 1 0 2 0 62 0 0 0 0
Rectal haemorrhage 58 0 2 0 0 62 0 0 0 0
Upper respiratory infection 52 3 3 2 0 62 0 0 0 0